Please login to the form below

Not currently logged in
Email:
Password:

Santhera CEO Klaus Schollmeier joins SuppreMol

He has experience at ING BHF-Bank, BASF, Knoll and Abbott

Santhera CEO Klaus Schollmeier joins SuppreMolFormer CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation in 2004, and was appointed chairman in October 2011.

He has both senior scientific and business experience, previously serving as managing director healthcare-biotechnology at ING BHF-Bank; head of oncology-immunology research at BASF; and general manager for BASF's operations in Western Europe.

Prior to his time at BASF, he held senior roles at Knoll and Abbott.

In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires.

Dr Thomas Hecht, chairman of the company's advisory board, paid tribute to Prof Buckell for his “long-standing commitment” as he welcomed Dr Schollmeier.

He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr Schollmeier will bring the necessary experience to the company to advance SuppreMol's products towards a Biologics License Application.”

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

5th April 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics